PRiME Vector Technologies GmbH

The Challenge: Companies in the vaccine industry are facing the challenge of producing highly effective customized vaccines in a quick and cost-effective way, both, in the fields of oncology and infectious diseases. Currently, neither is possible with the common platforms due to excessive development times, high costs of genuinely individualized vaccines, or an insufficient immune response.

The Solution: Our novel, safe viral vector platform enables the fast generation of mono- or polyvalent vaccines against infectious diseases and cancer. The application results in strong balanced B-/T-cell immune response without any adjuvant and without the necessity of vector virus multiplication. Multiple or prime-boost immunizations can be easily performed.

PRiME develops potent B and T cell vaccines based on attenuated Orf virus (Parapoxvirus) vectors with an excellent safety profile. Our vectors comprise tumor- or pathogen-specific antigens in a modular design. The accessory transgenes code for molecules/elements such as cytokines, activation signals, and/or checkpoint antibodies. Additionally, our system allows the customized combination of different antigen formats and different modes of antigen presentation. Due to our innovative selection system, these highly potent, flexible and safe vaccines will be available within a few weeks.